(RTTNews) - Quoin Pharmaceuticals, Inc. (QNRX), a clinical-stage specialty pharmaceutical company, on Wednesday, announced positive interim data from two ongoing clinical trials for topical lotion, QRX003, for Netherton Syndrome.
Netherton Syndrome is a rare hereditary skin disorder that causes severe skin barrier defects, frequent infections, and a heightened susceptibility to allergies, asthma, and eczema.
The drug is being tested in two key studies: an open-label study and a pediatric trial.
In the open-label study, the first subject dosed twice daily with QRX003 for six weeks showed significant clinical improvements.
The subject's Modified Ichthyosis Area of Severity Index (MIASI) decreased from 18 at baseline to 4, and the Investigator's Global Assessment (IGA) of disease severity improved from 'moderate' to 'mild'.
The subject also experienced a reduction in pruritus severity, from a score of 7 to 4 on the Worst Itch Numeric Rating Scale. Importantly, no safety concerns were reported, and patient satisfaction was high.
In Quoin's ongoing 12-week Investigator Pediatric Study, positive results were observed after just 12 days of treatment with QRX003. The subject's IGA classification improved from 'severe' to 'mild-moderate,' indicating a significant improvement in skin appearance.
No adverse events or safety concerns have been reported in the pediatric study to date.
Dr. Michael Myers, CEO of Quoin Pharmaceuticals, commented, "While these are interim data from a limited number of subjects, we are encouraged by the early results across both studies. The reductions in MIASI and pruritus severity in the open-label study, as well as the rapid improvement in skin condition in the pediatric study, are highly promising. We remain committed to developing QRX003 as a treatment for Netherton Syndrome."
Currently, Netherton Syndrome has no cure, and there are no approved therapeutic treatments available.
QNRX closed Tuesday's (Dec.17.2024) trading at $0.60, down 5.86%. In premarket trading, the stock is down another 8% at $0.55.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
